Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMPT-314 |
Synonyms | |
Therapy Description |
IMPT-314 comprises autologous naive/memory-enriched T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and CD20 and containing a TNFRSF9 (4-1BB) co-stimulatory domain, which may induce antitumor activity (Blood (2023) 142 (Supplement 1): 6892). |